On March 9, 2022, 16 months after the vaccine rollout in the US, the NIH launched a clinical trial of up to 100 people to study allergic reactions to a first dose of COVID-19 mRNA vaccine, where the second dose will be administered as an inpatient. [1, 2]
Adverse Events >>>